Evidence map›Paper›PMID 36358235›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Population Pharmacokinetics of Prophylactic Cefazolin in Cardiac Surgery with Standard and Minimally Invasive Extracorporeal Circulation.

Petr Šantavý, Martin Šíma, Ondřej Zuščich, Vendula Kubíčková, Danica Michaličková, Ondřej Slanař, Karel Urbánek

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Petr ŠantavýDepartment of Cardiac Surgery, Faculty of Medicine and Dentistry, Palacký University, University Hospital, Olomouc 779 00, Czech Republic.
Martin ŠímaDepartment of Pharmacology, First Faculty of Medicine, Charles University, General University Hospital, Prague 128 00, Czech Republic.ORCID 0000-0002-6541-738X
Ondřej ZuščichDepartment of Cardiac Surgery, Faculty of Medicine and Dentistry, Palacký University, University Hospital, Olomouc 779 00, Czech Republic.
Vendula KubíčkováDepartment of Pharmacology, Faculty of Medicine and Dentistry, Palacký University, University Hospital, Hněvotínská 3, 775 15 Olomouc, Czech Republic.
Danica MichaličkováDepartment of Pharmacology, First Faculty of Medicine, Charles University, General University Hospital, Prague 128 00, Czech Republic.ORCID 0000-0002-9690-9846
Ondřej SlanařDepartment of Pharmacology, First Faculty of Medicine, Charles University, General University Hospital, Prague 128 00, Czech Republic.
Karel UrbánekDepartment of Pharmacology, Faculty of Medicine and Dentistry, Palacký University, University Hospital, Hněvotínská 3, 775 15 Olomouc, Czech Republic.ORCID 0000-0002-3461-1649
Palacký University Olomouc · CZCharles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objectives of this study were to develop a population pharmacokinetic model of prophylactically administered cefazolin in patients undergoing cardiac surgery with and without the use of the cardiopulmonary bypass of both existing types-standard (ECC) and minimallyu invasive extracorporeal circulation (MiECC)-and to propose cefazoline dosing optimization based on this model. A total of 65 adult patients undergoing cardiac surgery were recruited to this clinical trial. A prophylactic cefazolin dose of 2 g was intravenously administered before surgery. Blood samples were collected using a rich sampling design and cefazolin serum concentrations were measured using the HPLC/UV method. The pharmacokinetic population model was calculated using a nonlinear mixed-effects modeling approach, and the Monte Carlo simulation was used to evaluate the PK/PD target attainment. The population cefazolin central volume of distribution (Vd) of 4.91 L increased by 0.51 L with each 1 m

Indexed as

antibiotic prophylaxiscardiopulmonary bypasscefazolineglomerular filtration ratenonlinear mixed-effects modeling

Identifiers

PMID36358235
PMCPMC9686470
OpenAlexW4308766783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.